No abstract available.
Angioplasty, Balloon, Coronary*

No abstract available.
Adult* ; Helicobacter pylori* ; Helicobacter* ; Humans ; Risk Factors*

A total of 48 cases of tuberculous lesion in the lymph nodes (43 cases), lung (3 cases) and soft tissue (2 cases), was subjected to fine needle aspiration cytology(FNAC). The age of the patients ranged from 19 to 77 year-old (average 33.6 years in age) and the male to female ratio was 1: 4. Thirty-four cases (70.8%) demonstrated distinct granulomatous reaction with or without caseation necrosis, nine cases (18.8%) showed no granulomas, but large amount of necrotic debris with numerous polymorphonuclear cells and histiocytes, and five cases (10.4%) revealed acellular material only. The overall AFB positivity in smears was 62.5%. In areas associated with granulomatous reaction and necrosis, AFB positivity was 55.8%, while it was 80.0% in cases with acellular necrotic material. There were 2 cases of parasitic infestation which could not be easily differentiated from tuberculosis based on aspiration smears only.
Aged ; Biopsy, Fine-Needle ; Child* ; Female ; Granuloma ; Histiocytes ; Humans ; Lung ; Lymph Nodes ; Male ; Necrosis ; Tuberculosis ; Vesico-Ureteral Reflux*

Nowadays, stent placement has replaced balloon angioplasty as the most commonly performed percutaneous coronary interventional procedure, mainly because of its improved acute and chronic outcome. As a result, however, in-stent restenosis (ISR) has become a widespread problem. The incidence of ISR varies from 10% to 50% and depends on the lesion characteristics and several risk factors, such as small vessel size, longer lesions, and diabetes. Intravascular ultrasound studies have demonstrated that ISR is mainly caused by neointimal proliferation; consequently, this pathologic process has become the target of many preventive and therapeutic approaches. Given the overall disappointment experienced with the use of systemic drug therapies for ISR prevention, stent devices have been coupled with local drug delivery to decrease neointimal proliferation. The results of many published preliminary studies with drug-eluting stents are excellent. However, it is important to remember that the number of treated patients receiving drug-eluting stents has been rather small, the duration of follow-up short, and the lesions treated relatively simple. It is still possible that drug-eluting stents simply delay, rather than eliminate, ISR. Nevertheless, drug-eluting stents remain a very promising therapy for IRS prevention. The results of the ongoing, larger, randomized trials could determine whether the goal of no restenosis can ultimately be achieved. If these studies of drug-eluting stents repeat the same positive results seen in preliminary trials, we can anticipate the advent of a new era in percutaneous intravascular revascularization, possibly reducing restenosis to a problem of the past.
Angioplasty, Balloon ; Angioplasty, Balloon, Coronary ; Coronary Restenosis ; Drug Therapy ; Drug-Eluting Stents ; Follow-Up Studies ; Humans ; Incidence ; Percutaneous Coronary Intervention* ; Risk Factors ; Stents* ; Ultrasonography

Nowadays, stent placement has replaced balloon angioplasty as the most commonly performed percutaneous coronary interventional procedure, mainly because of its improved acute and chronic outcome. As a result, however, in-stent restenosis (ISR) has become a widespread problem. The incidence of ISR varies from 10% to 50% and depends on the lesion characteristics and several risk factors, such as small vessel size, longer lesions, and diabetes. Intravascular ultrasound studies have demonstrated that ISR is mainly caused by neointimal proliferation; consequently, this pathologic process has become the target of many preventive and therapeutic approaches. Given the overall disappointment experienced with the use of systemic drug therapies for ISR prevention, stent devices have been coupled with local drug delivery to decrease neointimal proliferation. The results of many published preliminary studies with drug-eluting stents are excellent. However, it is important to remember that the number of treated patients receiving drug-eluting stents has been rather small, the duration of follow-up short, and the lesions treated relatively simple. It is still possible that drug-eluting stents simply delay, rather than eliminate, ISR. Nevertheless, drug-eluting stents remain a very promising therapy for IRS prevention. The results of the ongoing, larger, randomized trials could determine whether the goal of no restenosis can ultimately be achieved. If these studies of drug-eluting stents repeat the same positive results seen in preliminary trials, we can anticipate the advent of a new era in percutaneous intravascular revascularization, possibly reducing restenosis to a problem of the past.
Angioplasty, Balloon ; Angioplasty, Balloon, Coronary ; Coronary Restenosis ; Drug Therapy ; Drug-Eluting Stents ; Follow-Up Studies ; Humans ; Incidence ; Percutaneous Coronary Intervention* ; Risk Factors ; Stents* ; Ultrasonography

Disseminated intravascular coagulation (DIC) is a pathological syndrome in which activation of coagulation cascade leads to fibrin clot formation, consumption of platelets and coagulation factors, and secondary fibrinolysis. We report a case of severe postoperative hemorrhagic diathesis due to DIC. A 59-year-old man was scheduled for reduction of tibia fracture and anatrophic nephrolithotomy of staghorn calculi. On the fifth postoperative day, second operation was performed for nephrectomy due to perirenal hematoma. Two days later, third operation was performed for hemostasis because of the continuous bleeding. Coagulation tests showed positive DIC profiles of thrombocytopenia, hypofibrinogenemia, increased fibrin degradation products, and prolonged prothrombin time and thrombin time. The patient recovered uneventfully and discharged on the 59th postoperative day.
Blood Coagulation Factors ; Calculi ; Dacarbazine ; Disseminated Intravascular Coagulation* ; Fibrin ; Fibrin Fibrinogen Degradation Products ; Fibrinolysis ; Hematoma ; Hemorrhage* ; Hemorrhagic Disorders ; Hemostasis ; Humans ; Middle Aged ; Nephrectomy ; Postoperative Complications ; Prothrombin Time ; Thrombin Time ; Thrombocytopenia ; Tibia

No abstract available.
Lymphangioma, Cystic*

No abstract available.
Breast Neoplasms* ; Breast*

No abstract available.
Ankle*

No abstract available.
Osteoblastoma* ; Spine*